Bioxcel Therapeutics (BTAI) has disclosed a new risk, in the Accounting & Financial Operations category.
Bioxcel Therapeutics’ projections of market opportunity and addressable market for agitation episodes face significant uncertainties, relying heavily on varied internal and third-party estimates. If the actual number of treatable episodes or patient population size is substantially lower than estimated, or if medical community adoption and patient access challenges arise, the company’s revenue and path to profitability could be adversely affected. Particularly, discrepancies between third-party surveys and observational studies regarding treatable agitation episodes in patients with bipolar disorder and schizophrenia highlight the risks of overestimation. Such miscalculations could materially shrink Bioxcel’s addressable market, hindering business prospects and financial outcomes.
Overall, Wall Street has a Moderate Buy consensus rating on BTAI stock based on 3 Buys and 2 Holds.
To learn more about Bioxcel Therapeutics’ risk factors, click here.
